Patients with the AA genotype may have increased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.